Andover

Researchers are evaluating the safety and effectiveness of VSJ-110 ophthalmic solution compared to a placebo in treating dry eye. This is a Phase 2, double-masked, randomized, placebo-controlled study focused on adults with dry eye symptoms. The study aims to gather information about how VSJ-110 affects dry eye compared to no active medication over an eight-week period. Participants will be randomly assigned to receive either VSJ-110 or a placebo ophthalmic solution. The treatment period lasts for eight weeks, during which they will use the assigned eye drops as directed. No other active treatments will be given, and the study is designed to keep both participants and researchers unaware of which treatment is being used to ensure unbiased results. Throughout the study, participants will attend scheduled visits to monitor their eye health and treatment effects. Researchers will assess corneal staining to measure eye surface changes related to dry eye over the eight weeks. Safety and any side effects will also be closely observed to evaluate how well participants tolerate the treatment. The total study duration for each participant corresponds to the eight-week treatment period.

Researchers are studying two experimental drugs, REGN5713 and REGN5715, to see how they affect eye allergy signs and symptoms caused by birch tree pollen allergy in adolescents and adults. The goal is to evaluate the safety and effectiveness of these drugs, given alone or together, compared to a placebo. The study also aims to understand if the combination of the two drugs works differently than each drug by itself. Additionally, the research will explore possible side effects, how the drugs behave in the body, and whether participants develop antibodies against the drugs that could influence their effect or cause side effects. Participants will receive either REGN5713 alone, REGN5715 alone, the combination of REGN5713 and REGN5715, or a placebo, all given according to the study protocol. The study is randomized, double-masked, and placebo-controlled, conducted in a Phase 3 setting to assess the treatment impact on allergic conjunctivitis due to birch pollen. The treatments are administered as planned in the protocol, and participants undergo a Conjunctival Allergen Challenge to trigger eye allergy symptoms for assessment. During the study, researchers will measure the ocular itch score on Day 8 after the allergen challenge to compare the effects of the study drugs versus placebo. Other evaluations include safety monitoring, blood tests to measure drug levels, and checks for antibody development against the drugs. The study involves careful participant assessments to track allergy symptom changes, side effects, and overall treatment response in adolescents and adults with birch pollen-related eye allergies.